Summary
A bioRxiv preprint describes a genetic switch that uses lenalidomide to trigger the death of engineered human T cells, including CAR T cells. The work reports preclinical cell experiments, not clinical testing.
Researchers report a genetic safety switch that uses the drug lenalidomide to trigger the death of engineered T cells, including chimeric antigen receptor (CAR) T cells. The bioRxiv preprint, posted on October 1, 2026, describes experiments in primary human T cells and CAR T-cell models. The work offers a possible way to remove engineered cells if their activity needs to be curtailed; it is preclinical research, not a clinical study.
CAR T cells are living therapies engineered to recognise targets on cancer cells. Their sustained activity can be useful, but the preprint identifies difficult-to-control overactivation toxicities as a challenge. A drug-activated suicide switch is intended to give researchers a way to eliminate the modified cells when needed.
How the ICAD-CAD switch works
The system is built around CAD, an enzyme that can damage DNA, and ICAD, its chaperone and inhibitor. The researchers engineered T cells to express CAD alongside ICAD fused to a lenalidomide-inducible degron—a protein tag designed to make ICAD susceptible to drug-triggered destabilisation.
In the authors’ account, lenalidomide destabilises ICAD, releasing CAD to damage the cell’s DNA and induce cell death. The mechanism depends on CRBN, a lenalidomide-interacting adaptor in an E3 ubiquitin ligase pathway that helps mark proteins for degradation. A genome-wide CRISPR screen identified both CRBN and CAD as necessary for the switch to function.
The authors report that the ICAD-CAD construct remained expressed in primary human T cells over the long term without detectable unintended activation. They also report deep depletion of cells after drug treatment. The abstract does not give numerical depletion estimates, so these results are reported qualitatively.
Results in CAR T cells and potential use
When delivered alongside a CAR, the switch-equipped T cells retained their effector functions, according to the preprint, and could be rapidly depleted with lenalidomide. The researchers also report that the approach could be adapted to other systems for acutely destabilising proteins.
Lenalidomide is described by the authors as a broadly available, off-patent drug. Using an existing medicine as the trigger could make the switch more practical than systems that depend on a specialised controller drug. If further work supports the approach, a drug-triggered switch could provide a way to stop a cell therapy by removing the engineered cells, rather than relying only on reducing their activity.
The evidence described is from cell-based experiments; the preprint does not report treatment of patients or clinical safety outcomes. Several authors disclose that they are inventors on patents related to the work held by Mass General Brigham.